explore -WSS

explore

author：hotspot 2025-09-30 20:05:51 - browse：1875

Duchenne muscular dystrophy is a devastating disease and, until very recently, was one without much hope. When Hawken Miller was diagnosed at age 5, the physician told his parents to enjoy the time they had with him, as there wouldn’t be much. Over 20 years later, Miller is a journalist and content strategist for CureDuchenne, an organization started by his mother when he was diagnosed, and new treatment is on the horizon.

Last month, the FDA approved a new gene therapy from Sarepta Therapeutics that will provide hope for many patients and families. The new drug, however, has its limitations — it’s only approved for children age 4-5, for example. Miller joined the podcast to discuss how this drug may change lives, what more needs to happen, and what his personal experience has been living with Duchenne.

“For the older boys, we’re running up against the clock a little bit with what we’re able to do and what we’re not able to do,” Miller said. “And if we’re able to try anything that could possibly help, I think most people would like the opportunity to do that.”

The conversation is based off his recent First Opinion, “The FDA’s approval of a new gene therapy for Duchenne muscular dystrophy won’t help me — but it gives me hope.”

Be sure to sign up for the weekly “First Opinion Podcast” on Apple Podcasts, Stitcher, Google Play, or wherever you get your podcasts.

Previous article： Medicare proposal to cover medical devices draws a mixed reaction
Next article： My superpower is killing ticks

Wikipedia

hotspot

WSS

White House drug shortage group privately met with industry

Readout LOUD podcast: possible new ALS drug, artificial wombs

Why are Kaiser Permanente staff considering a strike?

Dramatically reducing cancer deaths requires the PASTEUR Act

Wild otter attack leads to woman being airlifted to hospital, 2 others treated for injuries

2 US Navy sailors arrested for allegedly spying for China

Wikipedia

explore

explore

At least 13 dead in Texas as scorching temps continue

Dramatically reducing cancer deaths requires the PASTEUR Act

Trump demands the U.S. pay no more for drugs than other countries … again

TytoCare raises $49 million to build out AI

ChatGPT in medicine: STAT answers readers' burning questions

Senators: Long

Medicare details structure of new drug price negotiation program

Verily hires former Apple Health leader as chief scientific officer

Peter Hotez and the public health issue of online harassment

Drug for rare kidney disease narrowly misses mark in clinical trial

entertainment

Stem cell clinics for heart failure: buyer be wary

What Mike Pence has said that could be used in a Donald Trump trial

Ukraine and a new approach to mental health in war

Lasker Awards 2023: Winners in biomedical research

It's been 20 years since Dolly the sheep. Where's my clone?

How Vertex's cystic fibrosis drug is changing patients' lives

Wikipedia

hotspot

hotspot

explore